Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2003
08/28/2003WO2003070275A1 Use of an inhibitor or antagonist against tissue factor
08/28/2003WO2003070270A1 Strategy for retroviral immunotherapy
08/28/2003WO2003070260A1 A photoprotective orally administrable composition for skin
08/28/2003WO2003070251A1 Pharmaceutical combinations of cox-2 inhibitors and opiates
08/28/2003WO2003070240A1 New treatment for arthrits and edematous processes
08/28/2003WO2003070237A1 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
08/28/2003WO2003070236A2 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003WO2003070235A1 Medicinal compositions for inhibiting tryptase
08/28/2003WO2003070234A1 Alkylating agent combinations in the treatment of cancer
08/28/2003WO2003070233A1 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
08/28/2003WO2003070231A1 Antibacterial compositions
08/28/2003WO2003070230A1 Use of agents that modulate pde11a activity
08/28/2003WO2003070221A1 Chemosensitizing with liposomes containing oligonucleotides
08/28/2003WO2003070216A1 System for transvaginal drug delivery
08/28/2003WO2003070204A2 Lipase inhibiting composition
08/28/2003WO2003070193A2 RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070192A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003WO2003070191A2 Tamper-resistant transdermal opioid delivery devices
08/28/2003WO2003070190A2 Surrogate antibodies and methods of preparation and use thereof
08/28/2003WO2003070188A2 Method of treating trx mediated diseases
08/28/2003WO2003070182A2 Sodium channel blockers
08/28/2003WO2003070177A2 Use of melatonin analogues for induction of general anesthesia
08/28/2003WO2003070167A2 Therapeutic and prophylactic treatment of aging and disorders of aging in humans
08/28/2003WO2003070157A2 Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
08/28/2003WO2003069997A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003WO2003069993A1 Antimicrobial therapeutic compositions and methods of use
08/28/2003WO2003049744B1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
08/28/2003WO2003045274A3 Thermopolymer composition and related methods
08/28/2003WO2003037384A3 Polymer conjugates of protein kinase c inhibitors
08/28/2003WO2003028711A3 Use of c-kit inhibitors for the treatment of myeloma
08/28/2003WO2003020202A3 Method for reducing hypertension and heart failure
08/28/2003WO2003014321A3 Compositions and methods for modulation of darpp-32 phosphorylation
08/28/2003WO2003014153A3 Cellular virus receptors and methods of use.
08/28/2003WO2003013434A3 Methods and compositions for treating diseases associated with excesses in ace
08/28/2003WO2003006017A3 Use of certain castanospermine esters in the treatment of influenza virus infections
08/28/2003WO2003004007A3 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
08/28/2003WO2003002105A3 Use of tyrosine kinase inhibitors for treating bone loss
08/28/2003WO2003002058A3 Bone anabolic compounds and methods of use
08/28/2003WO2002102990A3 Fibroblast growth factor and nucleic acid encoding same
08/28/2003WO2002096219A3 Acid controlled viscosity fiber system and uses thereof
08/28/2003WO2002079785A3 Phosphoprotein target for insulin and its antagonists
08/28/2003WO2002074337A8 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
08/28/2003WO2002074293A3 Methods for restoring cognitive function following systemic stress
08/28/2003WO2002074235A3 Heterocyclic compounds for therapeutic use
08/28/2003WO2002074048A8 P-glycoproteins and uses thereof
08/28/2003WO2002072534A3 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
08/28/2003WO2002062369A3 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
08/28/2003WO2002054073A3 Latent human tuberculosis model, diagnostic antigens, and methods of use
08/28/2003WO2002046749A3 Screening method for identifying compounds that selectively induce interferon alpha
08/28/2003WO2002044736A3 Diagnosis and treatment of epidermal or skin diseases
08/28/2003WO2002036149A3 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof
08/28/2003WO2002034940A3 Methods for screening compounds that modulate lipid metabolism
08/28/2003WO2002034922A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
08/28/2003WO2002028430A3 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
08/28/2003WO2002026244A3 Compositions and methods of use for extracts of rutaceae plants
08/28/2003WO2002015885A3 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
08/28/2003WO2002012326A3 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
08/28/2003WO2002008399A3 Human kinases
08/28/2003WO2002002780A3 Human serine-threonine kinase
08/28/2003WO2002000839A3 Statement as to federally sponsored research
08/28/2003WO2001082949A3 Method of reducing side effects of chemotherapy in cancer patients
08/28/2003US20030163834 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of Erk-5
08/28/2003US20030162946 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof
08/28/2003US20030162944 Nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors and uses thereof
08/28/2003US20030162837 Carboxyfullerenes and methods of use thereof
08/28/2003US20030162829 Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
08/28/2003US20030162824 Adminstering pyrazole derivatives
08/28/2003US20030162807 Compositions and methods for treating osteoporosis and lowering cholesterol
08/28/2003US20030162802 Preferential enzyme inhibitors such as 2-((4-6-pyrimidinedion -2-yl)amino)-4-methyl-5-thiazolecarboxylic acid ethyl ester, used for prophylaxis of lymphocyte associated disorders
08/28/2003US20030162796 Pharmaceutical composition for the treatment of disorders of non-human mammals
08/28/2003US20030162788 Administering to a mammal for reducing liver toxicity a heterocyclic amide compound as microsomal triglyceride transfer protein antagonist (fibrate)
08/28/2003US20030162782 Treating a patient suffering from neuropathy with sidenafil, free of 5-(3-pyridyl)pyrazoleo(4,3-d)pyrimidine-7-one, 2-(3-pyridyl)-4a,5-dihydroimidazo(5,1-f)(1,2,4)triazine-4(3H)-one or 2-phenylpurine-6-one, all are substituted
08/28/2003US20030162770 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
08/28/2003US20030162760 Dermal agent
08/28/2003US20030162759 Preventing or treating cardiovascular disease including atherosclerosis
08/28/2003US20030162758 Using regulation of pathogenic mechanisms similar to atherosclerosis; utilizing regulation of reverse cholesterol transport
08/28/2003US20030162757 Topically administering estrogen receptor antagonists
08/28/2003US20030162740 Strategy for leukemia therapy
08/28/2003US20030162736 Medicament comprising NK4 gene or recombinant NK4 protein
08/28/2003US20030162727 Use of cyp1b1inhibitors for treating cancer
08/28/2003US20030162725 Comprises 5-hydroxytryptophan (for enhancing serotonin-mediated neurotransmission), vitamin B6, epigallocatechin gallate (EGCG, for enhancing thermogenesis), caffeine, and anorectic agents
08/28/2003US20030162722 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors
08/28/2003US20030162716 Methods useful in the treatment of bone resorption diseases
08/28/2003US20030162709 Methods of generating multispecific, multivalent agents from VH and VL domains
08/28/2003US20030162695 Glucocorticoid blocking agents for increasing blood-brain barrier permeability
08/28/2003US20030162291 Clk-2, cex-7 and coq-4 genes, and uses thereof
08/28/2003US20030162278 Use for development of human therapeutic proteins; amino acid sequences, allelic variants, isolated polypeptide, antibody and nucleic acids, transgenic non-human animal, culturing the host cell, genetic engineering
08/28/2003US20030162274 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/28/2003US20030162256 PTH1R and PTH3R receptors, methods and uses thereof
08/28/2003US20030162223 Detection of insecticide; determination, calibration of binding to protein
08/28/2003US20030162196 Isolation nucleic acids; genetic engineering; diagnosis, therapy, prevention hematopoietic, nervous system disorders
08/28/2003US20030161899 For prophylaxis of inhalation allergic reactions comprising mixture of saturated hydrocarbons having viscosity of greater than 6 mm2/s123n; treatment of atopic rhinitis in the form of "hayfever"
08/28/2003US20030161892 Cumin in powder or oil form is blood clotter in combination with unctuous host substance including petroleum jelly, coconut butter and antiseptics
08/28/2003US20030161890 Administering composition comprising water and/or fat-soluble cytosolic extract of pollen combined with Royal Jelly and vitamin E for treatment of disorders related to hormonal variations during fertile, peri- and post menopausal age
08/28/2003US20030161877 Administering mixtures of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol -3-thione (oltipraz) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2, 2'-dicarboxylate (DDB) for prophylaxis of liver disorders; nontoxic
08/28/2003US20030161867 Skin-permeable selective cyclooxygenase-2 inhibitor composition
08/28/2003US20030161863 Administering mixtures of nutrients for prophylaxis of muscular, metabolic or respiratory disorders, injuries, inflammation and/or to relieve stress
08/28/2003US20030161858 Mixtures of cement powders, vitamins, hormones, antibiotics, antitumor agents, somatotropins, calcium phosphates or proteins dissolved, dispersed or emulsified in oils; bone disorders
08/28/2003US20030161846 Oral administration of an emulsion pre-concentrate of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat; forms an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability
08/28/2003US20030161836 Biological materials and methods useful in the diagnosis and treatment of diseases
1 ... 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 ... 1151